Serum interleukin-18 provides a clue to the diagnosis of adult-onset Still’s disease: findings from 6 Japanese patients with adult-onset Still’s disease.

Azusa Ogita, M.D., Ph.D.¹, Shin-ichi Ansai, M.D., Ph.D.¹, and Hidehisa Saeki, M.D., Ph.D.²

1) Division of Dermatology, Nippon Medical School Musashi Kosugi Hospital, Kawasaki, Japan

2) Department of Dermatology, Nippon Medical School. Tokyo, Japan

Correspondence: Azusa OGITA, M.D., Division of Dermatology, Nippon Medical School Musashi Kosugi Hospital,
1-396 Kosugi-cho, Nakahara-ku, Kawasaki, Kanagawa 211-8533, Japan
Tel: 81-44-733-5181 Fax: 81-44-711-8727
E-mail: azu@nms.ac.jp

Running title: Adult-onset Still’s disease
Abstract

Adult-onset Still’s disease (AOSD) is a systemic autoinflammatory disorder accompanied by skin eruption. However, typical skin eruptions, such as evanescent, salmon-pink erythema, are not specific to AOSD and dermatologists often face difficulty in diagnosing AOSD. Interleukin-18 (IL-18) is believed to be the initiating factor of the inflammatory cascade in AOSD and overproduction of IL-18 contributes to the development of systemic autoinflammatory reactions. Therefore, we examined serum IL-18 levels in the active and inactive phase of 6 Japanese patients with AOSD who visited our dermatology clinic over the past 10 years and compared with other markers, including IL-6, ferritin and C-reactive protein.

Key words: Steroid resistant, Interleukin-18, Interleukin-6, Adult-onset Still’s disease
Introduction

Adult-onset Still’s disease (AOSD) is one of the polygenic autoinflammatory diseases (AIDs) that exhibits no unique symptoms; thus, dermatologists often face difficulty in diagnosing AOSD. Although the pathogenesis of AOSD is not clearly understood, polygenic AIDs such as AOSD, systemic juvenile idiopathic arthritis, Kawasaki disease, and Behçet’s disease seem to share the same pathogenesis of hyperactivation of inflammasome and the overproduction of interleukin-1 cytokine family.\(^1\) In AOSD patients with a genetic background, trigger factors such as infections and chemical factors are transmitted to macrophages via Toll-like receptors, which leads to excessive activation of the NACHT, LRR and PYD domains-containing protein3 (NLRP3) inflammasome. This activation of NLRP3 enhances caspase-1 to cleave inactive pro-interleukin-1β (IL-1β) and pro-interleukin-18 (IL18) into mature IL-1β and IL-18. These cytokines are released from macrophage and stimulate innate immune cells such as monocytes, macrophage and dendritic cells as well as adaptive immune cells by activating Nuclear factor kappa B (NFκB), a transcription factor for pro-inflammatory cytokine genes, to increase the production of pro-inflammatory cytokines, including IL-1β, IL-6, IL-18, tumor necrosis factor (TNF-α), interferon-γ (IFN-γ), etc. This cycle contributes to the overproduction of pro-inflammatory cytokines and causes the acute phase reaction.\(^2,3\) Since the involvement of NLRP3 and the overproduction of downstream cytokines such as IL-18 has been suggested to play a pivotal role in AOSD, we suspected that detection of overproduced IL-18 and IL-6 will help diagnosing as AOSD. In this study, we investigated 6 Japanese cases of AOSD.
that were diagnosed over the past 10 years in our dermatology clinic and measured concentrations of serum IL-18 and IL-6, together with ferritin and C-reactive protein (CRP), to examine their potential as biomarkers for AOSD.

**Materials and Methods**

*Patients.* To evaluate the serum levels of IL-6, IL-18 and laboratory data, 6 Japanese patients with AOSD who visited our dermatology clinic of Nippon Medical School Hospital over the last 10 years were enrolled. The patients that had no signs or infection, malignancy or rheumatic disease were carefully diagnosed based on the Yamaguchi criteria for AOSD. Ultimately, six patients with AOSD (1 man and 5 women) were enrolled. Their mean age at the time of diagnosis was 39 years (range: 22 to 53 years). All six patients had skin rashes at the time of visiting our clinic. One patient (case 2) presented with the typical evanescent, salmon-pink erythema with fever (Fig.1a). The other five patients had persistent pruritic erythema. Of them, one patient (case 6) presented with persistent pruritic papules and plaques (Fig.1b). Scratch dermatitis-like lesions were observed in 2 patients (case 2 & 6) (Fig. 1c, d). Skin biopsies were performed on 4 patients with persistent, pruritic eruption (case1, 4, 5, 6). Histopathologically, all four cases exhibited perivascular and/or interstitial
infiltrate of lymphocytes, neutrophils and eosinophils in the dermis. Interface change was observed in 2 cases (case 4 and 6) and the other 2 cases (case 1,5) showed no epidermal changes. The histopathological findings of persistent pruritic papules and plaques in case 6 consisted of mounded parakeratosis, dyskeratotic cells in the epidermis and interface change at the basal layer, as well as superficial perivascular and interstitial infiltration of lymphocytes, neutrophils and numerous eosinophils in the dermis, supporting the distinct and specific findings of persistent pruritic papules and plaques.\(^5\)

**Measurement of serum IL-6, IL-18.** Serum levels of IL-6 (normal range: \(\leq 4.0\text{pg/ml}\)) and IL-18 (normal range: 126pg/ml±44.5 pg/ml) were evaluated in the acute phase before treatments and at the time of remission (no fever, no rash, no arthralgia, no lymph node swelling and normalized CRP) in 5 patients. Serum levels of IL-6 were analyzed using a commercial chemiluminescent enzyme immunoassay (CLEIA; SRL, Tokyo, Japan). Serum IL-18 levels were measured using a commercial ELISA kit (Medical & Biological Laboratories Co., LTD. Nagoya, Japan) by way of BML, INC. (Case 1) and SRL, INC. (Case 2, 3, 5, 6). Serum CRP (normal range: 0-0.3mg/dl) and ferritin (normal range: 10-60pg/ml) levels were also evaluated before and after treatment in 6 patients.
Results

Laboratory findings (CRP and ferritin) and changes in serum of IL-6 and IL-18 levels before and after treatment (Table 1). In active AOSD, serum ferritin levels and CRP levels were above normal range, from 307.6 to 4692ng/ml and from 5.33 to 29.24mg/dl, respectively; in 6 patients. In remission, serum ferritin levels of 3 patients were slightly above the normal range, while CRP serum levels of 6 patients were all normalized.

Serum IL-18 levels were markedly elevated in 5 cases during the acute phase. In case 1, while serum the serum IL-18 level was highly elevated (184497pg/ml) at onset, in remission it remained at a high level (24144pg/ml). Serum IL-18 levels in 4 cases (case 2, 3, 5,6) were above the upper-limit of detection of the ELISA kit (≥5000pg/ml) and final serum IL-18 levels in 4 cases were not obtained. The reasons are as follows. First, the tests were conducted by other laboratory company in which serum samples were not diluted to get the final serum IL-18 levels. Second, the samples were tested one or two months after a blood test depending on the number of samples collected, causing a delay in the IL-18 results. In remission, serum IL-18 levels remained at higher values than the normal range in 5 cases. In cases 1 and 2, the serum IL-18 levels remained
remarkably high (≥5000pg/ml) after remission.

Serum IL-6 levels were also highly elevated in 5 patients in active AOSD and became normalized in remission after treatment except in case 2. Interestingly, in case 5, when the AOSD recurred, serum cytokine levels, such as IL-18 and IL-6, rose faster than ferritin and serum IL-18 elevated sharply (4530pg/ml) compared with IL-6 level (8.6pg/ml).

Discussion

IL-18, a proinflammatory cytokine of IL-1 superfamily, plays a significant role in stimulating innate immune cell activation as well as adaptive immune cells, causing overproduction of several inflammatory cytokines in AOSD. In this study, serum IL-18 levels in 5 patients were elevated significantly higher than normal values and remained higher, even after treatment. A previous report supports our data that IL-18 levels in AOSD were much higher (mean±SD 99,000±99,800pg/ml) than those in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis, polymyositis/dermatomyositis, and Sjögren’s syndrome (SS), and in healthy controls. Colafrancesco et al. also concluded that AOSD patients could be
discriminated from RA, SLE, and SS patients and from healthy subjects by the serum level of IL-18 determined by ELISA. Furthermore, Kim et al.\textsuperscript{8} described that with a cutoff value of 366.1 pg/ml, the sensitivity and specificity of IL-18 was highest for the diagnosis of AOSD (91.7\% and 99.1\%, respectively). Therefore, detection of the overproduction of IL-18 will be clue to the diagnosis of AOSD. Interestingly, some previous studies showed that IL-18 levels were gradually reduced in patients with AOSD after symptoms disappeared by treatment and remained detectable beyond the values in healthy controls, even a few weeks after normalization of the inflammatory reaction\textsuperscript{6,9} consistent with our observations of serum IL-18 levels after treatment. In particular, in cases 1 and 2, the serum IL-18 levels remained high (≥5000 pg/ml) even after remission. In these cases, the AOSD was refractory to high dose of systemic corticosteroids and the patients were treated twice with intravenous pulse glucocorticoids therapy together with an immunosuppressant. Furthermore, in case 2, the patient was treated with Tocilizumab, a monoclonal antibody against IL-6 receptor. Our result indicates that high levels of serum IL-18 correlate with disease severity and refractory cases and the role of IL-18 as a marker of disease activity in AOSD is questionable. Although the cause of high serum IL-
18 levels in remission remains unclear, we suspect that it may cause by the overproduction of IL-18 levels in organs or tissues, such as lymph node and liver in AOSD\textsuperscript{10-11}, resulting in the delay of normalization of serum IL-18 levels.

IL-6 is a pro-inflammatory cytokine secreted by macrophages, activated T cells, B cells and some other cells, which attributes to the production of acute-phase protein and to the activation of B cells for producing antibodies. In our studies, we found out that serum IL-6 levels were elevated at the onset; however, it does not appear to be a reliable diagnostic marker. Kawashima et al.\textsuperscript{5} demonstrated that increased serum IL-6 was generally detected at higher levels in AOSD patients compared with RA patients; although the difference between the two groups was not statistically significant. Furthermore, Rau et al.\textsuperscript{12} proved that IL-6 cannot differentiate AOSD patients from patients with sepsis. Therefore, serum IL-6 level is not a specific marker for the diagnosis of AOSD. While IL-6 levels have been considered to correlate with disease activity\textsuperscript{9,13}, in case 2, IL-6 remained elevated even after remission. Based upon our findings, CRP levels appear to be more useful in observing disease activity in AOSD.

Hyperferritinemia in AOSD is mainly attributable to increased ferritin released from the liver and spleen\textsuperscript{6,14}. IL-18 stimulates innate immune cells such as
Kupffer cells in liver and splenic macrophages for erythrophagocytosis to release the iron in the form of ferritin. IL-18 contributes to hyperferritinemia and high level of serum ferritin has been said to be a diagnostic marker of AOSD and correlate with its disease activity. However, serum ferritin levels in our cases increased and decreased gradually in the active and inactive state, compared with IL-6, IL-18, and CRP.

The clinical features of skin eruption in AOSD vary and they are categorized into 2 distinct cutaneous eruptions, one is the typical evanescent, salmon-pink rash, and the other is an atypical persistent, pruritic or non-pruritic rash. The most representative lesion among the atypical skin rashes is persistent pruritic papules and/or plaques, as seen in case 6. The scratch dermatitis-like lesions observed in 2 cases may be among the characteristic eruptions observed in AOSD, presenting as excoriation marks or as a reflection of Koebner’s phenomenon. In our cases, there were no correlations between the types of skin eruptions and serum IL-18 and IL-6 levels.

In summary, high levels of serum IL-18 will be a clue to the diagnosis of AOSD. Commercial-based IL-18 ELISA kits in Japan are not actually convenient because the test is not covered by medical insurance, and serum samples are
pooled and tested all together a few weeks after a blood test, causing a delay in the IL-18 results. We suggest that IL-18 ELISA kits need to be more practical for use in daily practice. CRP is also useful biomarker for monitoring disease activity compared with IL-6 and IL-18.

CONFLICT OF INTEREST: None declared.
References

1. Malcova H, Milota T, Strizova Z et al. Interleukin-1 blockade in polygenic autoinflammatory disorders: where are we now? *Front Pharmacol* 2021; 11: 619273.

2. Mitrovic S, Fautrel B. New markers for adult-onset Still’s disease. *Joint Bone Spine* 2018; 85: 285-93.

3. Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. *Nat Rev Rheumatol* 2018; 14: 603-18.

4. Yamaguchi M, Ohta A, Tsunematsu T et al. Preliminary criteria for classification of adult Still’s disease. *J Rheumatol* 1992; 19:424-30.

5. Lee JY, Yang CC, Hsu MM. Histopathology of persistent papules and plaques in adult-onset Still’s disease. *J Am Acad Dermatol* 2005; 52:1003-8.

6. Kawashima M, Yamamura M, Taniai M et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still’s disease. *Arthritis Rheum* 2001; 44: 550-60.

7. Colafrancesco S, Priori R, Alessandri C et al. IL-18 serum level in adult onset Still’s disease: a marker of disease activity. *Int J Inflam* 2012; 156890.
8. Kim HA, An JM, Nam JY, et al. Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still’s disease. J Reumatol 2012; 39: 1399-406.

9. Choi JH, Suh CH, Lee YM, et al. Serum cytokine profiles in patients with adult onset Still’s disease. J Rheumatol 2003; 30: 2422-7.

10. Conigliaro P, Prior R, Bombardieri M et al. Lymph node IL-18 expression in adult-onset Still’s disease. Ann Rheum Dis 2009; 68:442-3.

11. Priori R, Barone F, Alessandri C et al. Markedly increased IL-18 liver expression in adult-onset Still’s disease-related hepatitis. Rheumatology 2011; 50: 776-80.

12. Rau M, Schiller M, Krienke S, et al. Clinical manifestations but not cytokine profiles differentiate adult-onset Still’s disease and sepsis. J Rheumatol 2010; 37: 2369-76.

13. Chen DY, Lan JL, Lin FJ, et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol 2004; 31: 2189-98.

14. Van Reeth C, le Moel G, Lasne Y, et al. Serum ferritin and isoferritins are tools for diagnosis of active adult Still’s disease. J Rheumatol 1994; 21:890-
15. Ota T, Higashi S, Suzuki H, *et al.* Increased serum ferritin levels in adult Still’s disease. *Lancet* 1987; 1:562-3.

16. Fautrel B, Le Moël G, Saint-Marcoux B, *et al.* Diagnostic value of ferritin and glycosylated ferritin in adult-onset Still’s disease. *J Rheumatol* 2001; 28:322-9.
**Figure Legends**

Figure 1. Skin rashes in cases 2 and 6.

a. Case 2. Typical rash seen in AOSD. An evanescent, salmon-pink, erythema on the knee.

b. Case 6. Persistent pruritic, violet to brownish, papules and plaques on the abdomen.

c. Case 2. Scratch dermatitis-like lesion on the back.

d. Case 6. Scratch dermatitis-like lesion on the back.
| Case | Age | Sex | Skin eruptions | IL-18 (126.0±44.5pg/ml) | IL-6 (≤4.0pg/ml) | Ferritin (10-60 ng/ml) | CRP (≤0.3mg/dl) | Remarks |
|------|-----|-----|----------------|------------------------|-----------------|----------------------|----------------|---------|
| 1    | 48  | F   | Persistent pruritic erythema | 184497 | 24144 | 184.65 | 1.64 | 307.6 | 66.5 | 5.33 | 0 | In case 5, when AOSD recurred, IL-18 and IL-6 levels rose faster than ferritin (within normal range), 4530pg/ml and 8.6pg/ml, respectively. |
| 2    | 53  | F   | Evanescent, salmon-pink, erythema; scratch dermatitis-like lesion | ≥5000 | ≥5000 | 130 | 11.4 | 4439 | 167 | 29.24 | ≤0.1 |
| 3    | 45  | F   | Persistent pruritic erythema | ≥5000 | ND | 381 | ND | 4692 | ND | 23.48 | ND |
| 4    | 27  | M   | Persistent pruritic erythema | ND | 169 | ND | 0.6 | 441 | 246 | 15.46 | ≤0.1 |
| 5    | 22  | F   | Persistent pruritic erythema | ≥5000 | 1390 | 35.7 | 2.3 | 1106 | 20 | 7.35 | ≤0.1 |
| 6    | 39  | F   | Persistent pruritic papules and plaques; scratch dermatitis-like lesion | ≥5000 | 4940 | 10.5 | 2.2 | 1361 | 18 | 9.66 | ≤0.1 |

IL-18, interleukin-18; CRP, C-reactive protein; ND, not done.
Remission: no fever, no rash, no arthralgia, no lymph node swelling and normalized CRP.
IL-18 values in case 2, 3, 5 and 6 are greater than 5000pg/ml (≥5000pg/ml). Final values of IL-18 were not obtained because they were tested at other laboratory company.